| 2922 |
Ataxia with isolated vitamin E deficiency |
1 |
Target evidence
|
62.8 |
| 2926 |
Retinal atrophy, progressive, GTPBP2-related |
1 |
Target evidence
|
56.0 |
| 2939 |
Epileptic encephalopathy, CAD-related |
1 |
Target evidence
|
57.1 |
| 2951 |
Cardiomyopathy, hypertrophic, MYBPC3-related, autosomal dominant |
1 |
Target evidence
|
58.5 |
| 2952 |
Cardiomyopathy, hypertrophic, MYBPC3-related, autosomal recessive |
1 |
Target evidence
|
58.5 |
| 2958 |
Rhizomelic chondrodysplasia punctata, GNPAT-related |
1 |
Target evidence
|
42.0 |
| 2967 |
Plasminogen activator inhibitor-1 deficiency, SERPINE1-related |
1 |
Drug
|
75.5 |
| 2976 |
Macular dystrophy, BEST1-related |
1 |
Target evidence
|
58.6 |
| 3010 |
Polyglucosan body myopathy, RBCK1-related |
1 |
Target evidence
|
62.9 |
| 3026 |
Porencephaly, SLC25A12-related |
1 |
Target evidence
|
57.0 |
| 3028 |
Retinal atrophy, cone-rod dystrophy, SPATA7-related |
1 |
Target evidence
|
54.6 |
| 3038 |
Paw pad hyperkeratosis, GJB6-related |
1 |
Target evidence
|
57.9 |
| 3039 |
Curly coat, KRT25-related |
1 |
Target evidence
|
53.0 |
| 3045 |
Autoimmune lymphoproliferative syndrome, FAS-related |
1 |
Target evidence
|
59.9 |
| 3046 |
Retinal atrophy, progressive, CACNA1F-related |
1 |
Drug
|
59.6 |
| 3047 |
Polycystic kidney disease, GANAB-related |
1 |
Target evidence
|
61.7 |
| 3048 |
Vestibular disease, PCDH15-related |
1 |
Target evidence
|
54.7 |
| 3056 |
Myopathy, creatine deficiency disorder, GATM-related |
1 |
Target evidence
|
58.6 |
| 3057 |
Cerebellar atrophy, EMC1-related |
1 |
Target evidence
|
60.9 |
| 3058 |
Ataxia, SETX-related |
1 |
Target evidence
|
58.1 |
| 3072 |
Polysynovitis, HYAL1-related |
1 |
Target evidence
|
56.3 |
| 3080 |
Dystroglycanopathy, POMT1-related |
1 |
Target evidence
|
57.8 |
| 3081 |
Usher syndrome, WHRN-related |
1 |
Target evidence
|
53.8 |
